drugset / Trial / NCT00823199

An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

NCT00823199

Completed 10 enrolled Bronx Psychiatric Center
NaSingle-groupOpen-labelTreatment

Summary

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Timeline

Start
2005-11
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopurinol Small molecule 300 mg Oral

Indications